Webinar: antibody patents in Europe and beyond
06-08-2020
LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF
22-03-2018
Webinar: Plausibility differences determine patent variations in US and EU
28-09-2017
01-02-2018
man_at_mouse / iStockphoto.com
When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch (BSKB).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
patenting antibodies, BSKB, patentability, 101, PTAB, antigen, Gerald Murphy, John Heithaus, US patents, antigen patents